Clinical Trials on Subjective Cognitive Complaints in Argentina

Total 10 results

Hospital Italiano de Buenos Aires

Completed

Post Operative Cognitive Dysfunction (POCD)

Postoperative Complications

Argentina
National Council of Scientific and Technical Research...

Completed

Naturalistic Study of Microdosing With Psilocybin (NATMICRO)

Sleep | Cognitive Change | Mood Change | Creativity

Argentina
FORUM Pharmaceuticals Inc
Syneos Health; NeuroCog Trials, Inc.

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Australia, Poland, Ukraine, Germany, Spain, Argentina, Serbia, Canada, Singapore, Russian Federation, Brazil, Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

Mild Cognitive Impairment

United States, United Kingdom, Belgium, Germany, Spain, Argentina, Israel, Poland, Australia, Canada, Netherlands, Finland, Austria, Sweden, France, Czech Republic
FORUM Pharmaceuticals Inc
Syneos Health; NeuroCog Trials, Inc.

Completed

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Poland, Romania, Russian Federation, Italy, Mexico, Colombia, Argentina, Australia, Brazil
FORUM Pharmaceuticals Inc
Syneos Health

Completed

A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Schizophrenia | Impaired Cognition

United States, Ukraine, United Kingdom, Germany, Spain, Argentina, Canada, Singapore, Russian Federation, Italy, Mexico, Colombia, Australia, Belgium, Poland, Romania
Hospital Italiano de Buenos Aires

Completed

Cognitive Performance After a Night Shift in Internal Medicine Residents

Burnout, Professional | Cognition Disorders | Sleep Deprivation

Argentina
Hoffmann-La Roche

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Huntington Disease

United States, Australia, Argentina, Canada, Germany, Italy, Spain, France, United Kingdom, Portugal, New Zealand, Austria, Poland, Switzerland, Denmark
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Huntingtons Disease

United States, United Kingdom, Australia, Canada, Japan, Poland, Netherlands, Germany, Russian Federation, France, Spain, Argentina, New Zealand, Austria, Denmark, Italy, Switzerland, Chile
CHDI Foundation, Inc.

Recruiting

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Huntington's Disease

United States, Canada, Belgium, Spain, Australia, Germany, France, Netherlands, United Kingdom, New Zealand, Argentina, Austria, Chile, Colombia, Denmark, Ireland, Italy, Poland, Portugal, Switzerland

Clinical Trials on Subjective Cognitive Complaints in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations